Avian Influenza is an indication for drug development with over 60 pipeline drugs currently active. According to GlobalData, preregistered drugs for Avian Influenza have a 100% likelihood of approval (LoA) indication benchmark. GlobalData’s report assesses how phase transition success rate (PTSR) and likelihood of approval (LoA) scores for pipeline drugs in Avian Influenza compared to historical benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Avian Influenza overview
Avian influenza, commonly referred to as bird flu, is a viral infection that primarily affects birds, especially poultry such as chickens and turkeys. Various strains of avian influenza viruses exist, some of which can cause severe illness in birds and, in certain cases, pose a risk to human health. Avian influenza viruses belong to the influenza A virus family and are classified based on surface proteins: hemagglutinin (H) and neuraminidase (N). The H5, H7, and H9 subtypes are of particular concern due to their potential to cause severe disease in birds and occasionally transmit to humans. Avian influenza viruses primarily circulate among birds and can spread through direct contact with infected birds, their feces, respiratory secretions, or contaminated surfaces. Human infections often occur through close contact with infected birds or environments contaminated with the virus. While most avian influenza viruses do not infect humans, certain strains, particularly H5N1, H7N9, and others, have caused sporadic cases of severe illness and even death in humans. Human infections are rare but can occur following direct contact with infected birds, particularly in settings such as live bird markets or farms.
See Also:
For a complete picture of PTSR and LoA scores for drugs in Avian Influenza, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
